Rhumbline Advisers Raises Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Rhumbline Advisers raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 3.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 321,154 shares of the biotechnology company’s stock after purchasing an additional 12,022 shares during the quarter. Rhumbline Advisers owned 0.15% of BioCryst Pharmaceuticals worth $2,409,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of BCRX. Headlands Technologies LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth about $32,000. GF Fund Management CO. LTD. purchased a new position in BioCryst Pharmaceuticals during the fourth quarter worth about $33,000. GAMMA Investing LLC raised its stake in shares of BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 5,449 shares during the period. New Age Alpha Advisors LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter valued at approximately $62,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $79,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director directly owned 65,352 shares of the company’s stock, valued at $556,145.52. This trade represents a 51.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

BCRX has been the subject of several research analyst reports. Bank of America raised their price target on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, July 1st. Wedbush boosted their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a research note on Monday, June 30th. Royal Bank Of Canada reissued an “outperform” rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Needham & Company LLC restated a “buy” rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Finally, Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 26th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.70.

BioCryst Pharmaceuticals Trading Up 0.6%

NASDAQ BCRX opened at $7.75 on Wednesday. The business’s 50 day moving average is $8.39 and its two-hundred day moving average is $8.72. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -43.05, a PEG ratio of 1.55 and a beta of 1.13. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.01 and a 12-month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.12. The business had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. During the same period last year, the business posted ($0.06) EPS. BioCryst Pharmaceuticals’s revenue was up 49.5% compared to the same quarter last year. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.